explore -WSS

explore

author：knowledge 2025-10-02 19:20:43 - browse：3328

Christine Kao/STAT

The Food and Drug Administration’s approval on Friday of two gene therapies for sickle cell disease sets up what could be an intense competition between Bluebird Bio, maker of Lyfgenia, and the partnership of Vertex Pharmaceuticals and CRISPR Therapeutics, whose drug is Casgevy.

For the first time, physicians and patients will have a choice of potentially curative treatments for an inherited disease that affects nearly 100,000 Americans.

The Vertex/CRISPR team would seem to have the edge. As the first CRISPR-based therapy, Casgevy has the advantage of being powered by the latest and buzziest biological technology, though some physicians and patients may be more comfortable with the lentiviral vector technology behind Lyfgenia, which dates back to the 1990s — even with a “black box” warning of a risk of blood cancer added to its label.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： A controversial new treatment promises to make little people taller

Wikipedia

WSS

Judge partially blocks Texas abortion ban for medical emergencies, fatal diagnoses

Pharma showers House GOP doctor with campaign cash

Study links childhood stress with decline in older age

FDA scientists endorse Pfizer/BioNTech Covid

CDC recommends RSV monoclonal antibody for infants

Ebola vaccine can save some who are already sick, per new study

entertainment

explore

explore

Jerome Adams on the need for new antivirals for Covid

Bernie Sanders gets little from pharma CEOs on drug prices

Apple is now the first public company to be valued at $3 trillion

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

ChatGPT in medicine: STAT answers readers' burning questions

FAA sets up new process for Hawaii air tour operators to fly at lower altitudes after fatal crashes

Cancer drug shortages should be causing more outrage

The a glaring gap in research on serious mental illness and primary care

Malaria cases in Florida and Texas: Here’s what you need to know

AMAs digital advisors table RPM coding reform proposal, again

focus

Eli Lilly reports tirzepatide MASH success during Q4 earnings

Who is Jack Smith, the special counsel overseeing the DOJ's Trump probes?

AMAs digital advisors table RPM coding reform proposal, again

Juul documents reveal insider tactics on political lobbying

AMAs digital advisors table RPM coding reform proposal, again

Tome Biosciences co

Wikipedia

knowledge

Wikipedia

leisure time